4.5 Article

The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases

Journal

PROSTATE CANCER AND PROSTATIC DISEASES
Volume 13, Issue 1, Pages 87-93

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/pcan.2009.48

Keywords

prostatectomy; prostate-specific antigen; nomograms; validation studies; disease-free survival

Funding

  1. Department of Veterans Affairs, National Institute of Health [R01CA100938]
  2. NIH [P50 CA92131-01A1]
  3. Georgia Cancer Coalition
  4. Department of Defense, Prostate Cancer Research Program
  5. American Urological Association Foundation/Astellas Rising Star in Urology Award

Ask authors/readers for more resources

To evaluate whether race modifies the accuracy of nomograms to predict biochemical recurrence (BCR) after radical prostatectomy among subjects from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center (DPC) databases. Retrospective analysis of 1721 and 4511 subjects from the SEARCH and DPC cohorts, respectively. The discrimination accuracy for BCR of seven previously published predictive models was assessed using concordance index and compared between African-American men (AAM) and Caucasian men (CM). AAM represented 44% of SEARCH and 14% of DPC. In both cohorts, AAM were more likely to experience BCR than CM (P<0.01). In SEARCH, the mean concordance index across all seven models was lower in AAM (0.678) than CM (0.715), though the mean difference between CM and AAM was modest (0.037; range 0.015-0.062). In DPC the overall mean concordance index for BCR across all seven nomograms was 0.686. In contrast to SEARCH, the mean concordance index in DPC was higher in AAM (0.717) than CM (0.681), though the mean differences between CM and AAM was modest (-0.036; range -0.078 to -0.004). Across all seven models for predicting BCR, the discriminatory accuracy was better among CM in SEARCH and better among AAM in DPC. The mean difference in discriminatory accuracy of all seven nomograms between AAM and CM was approximately 3-4%. This indicates that currently used predictive models have similar performances among CM and AAM. Therefore, nomograms represent a valid and accurate method to predict BCR regardless of race. Prostate Cancer and Prostatic Diseases (2010) 13, 87-93; doi:10.1038/pcan.2009.48;published online 17 November 2009

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD

Ronald de Wit, Stephen J. Freedland, Stephane Oudard, Georgi Marinov, Philippe Capart, Austin J. Combest, Ryan Peterson, Ayse Ozatilgan, Alicia K. Morgans

Summary: This study compared the characteristics and treatment patterns of real-world prostate cancer patients with those of the population in the CARD study, and found that the treatment responses were similar in both populations.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Article Oncology

Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer

John M. Masterson, Michael Luu, Aurash Naser-Tavakolian, Stephen J. Freedland, Howard Sandler, Zachary S. Zumsteg, Timothy J. Daskivich

Summary: The number and density of metastatic lymph nodes on lymphadenectomy predict mortality in prostate cancer. The study found that the impact of lymph node density on overall mortality is negligible in patients with 3 or fewer metastatic lymph nodes, who make up the majority of patients with metastatic lymph nodes. Pathological nodal staging should primarily focus on the count of lymph nodes rather than density.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Article Oncology

The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence

Sanjay Das, Lin Gu, Claire Trustram Eve, Joshua Parrish, Amanda M. De Hoedt, Chad Mckee, William Aronson, Stephen J. Freedland, Stephen B. Williams

Summary: In this study, we evaluated the outcomes of bladder cancer in 378 NMIBC patients and compared the differences between BLC and white light alone. The results showed that BLC significantly reduced the risk of recurrence compared to white light alone, and there was no difference in outcomes between Black and White race.

CLINICAL GENITOURINARY CANCER (2023)

Letter Medicine, General & Internal

Prostate Cancer in Transgender Women in the Veterans Affairs Health System, 2000-2022

Farnoosh Nik-Ahd, Amanda De Hoedt, Christi Butler, Jennifer T. Anger, Peter R. Carroll, Matthew R. Cooperberg, Stephen J. Freedland

Summary: This case series examined the frequency of prostate cancer diagnoses in transgender women receiving care at the Veterans Affairs health system.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Article Urology & Nephrology

Seeing the unseen: how can we best identify transgender women within the Veterans Affairs healthcare system's electronic medical record?

Farnoosh Nik-Ahd, Justin Waller, Amanda M. DeHoedt, Maurice M. Garcia, Jane C. Figueiredo, Peter R. Carroll, Matthew R. Cooperberg, Stephen J. Freedland

Summary: The study aimed to explore the sensitivity and specificity of five commonly used ICD codes in identifying transgender patients, specifically transgender women, using data from the Veterans Affairs. The results showed that these ICD codes are highly sensitive in identifying transgender patients, and the combination with orchiectomy is extremely sensitive in identifying transgender women.

JOURNAL OF SEXUAL MEDICINE (2023)

Article Oncology

A modeling study to estimate prostate cancer-specific mortality on active surveillance for men with favorable intermediate-risk prostate cancer: Results from the SEARCH cohort

Paige K. Kuhlmann, Taofik Oyekunle, Zachary Klaassen, Christopher L. Amling, William J. Aronson, Matthew R. Cooperberg, Christopher J. Kane, Martha K. Terris, Stephen J. Freedland

Summary: This study aimed to provide data support for the choice between active surveillance (AS) and treatment for men with favorable intermediate risk (FIR) prostate cancer. By retrospectively reviewing data from a cohort of men undergoing radical prostatectomy (RP), the theoretical risk of prostate cancer-specific mortality (PCSM) with AS was estimated and compared to RP. The results showed that even with a 1.25x to 2x increased risk of PCSM compared to RP, the risk of death for FIR men choosing AS is still low, up to 15 years.

CANCER MEDICINE (2023)

Article Biochemical Research Methods

The Streaming Web-Based Exercise at Home Study for Breast and Prostate Cancer Survivors: A Feasibility Study Protocol

Celina H. Shirazipour, Rachel M. Ruggieri-Bacani, Laura Lockshon, Christopher Waring, Aubrey Jarman, Novalyn Cruz, Catherine Bresee, Angela J. Fong, Pao-Hwa Lin, Gillian Gresham, Arash Asher, Stephen J. Freedland

Summary: This study aims to investigate the feasibility of personalized Zoom-delivered exercise training for breast and prostate cancer survivors, as well as the preliminary efficacy of participation on various health indicators. A 24-week feasibility study will be conducted, involving virtual personal training via Zoom and follow-up exercise using recorded sessions. Physical assessments and surveys will be conducted at multiple time points. Further research is needed to understand the feasibility and effectiveness of virtual exercise programming.

METHODS AND PROTOCOLS (2023)

Article Oncology

Impact of Asian Race on Prognosis in De Novo Metastatic Prostate Cancer

Xudong Ni, Michael Luu, Weiwei Ma, Tingwei Zhang, Yu Wei, Stephen J. Freedland, Dingwei Ye, Timothy J. Daskivich, Yao Zhu

Summary: Asian males with de novo metastatic prostate cancer have better overall survival and cancer-specific survival compared to white males across different treatment regimens.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2023)

Review Oncology

Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification

Neal D. Shore, Judd W. Moul, Kenneth J. Pienta, Johannes Czernin, Martin T. King, Stephen J. Freedland

Summary: Risk stratification is crucial for the management of patients with biochemical recurrence, as it guides the selection of treatment strategies and estimation of adverse events.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Article Oncology

Relative search popularity of five advanced prostate cancer medications using Google Trends

Sanjay Das, Nadine A. Friedrich, James Daniels, G. Cecilia Galvan, Jun Gong, Edwin Posadas, William Aronson, Stephen J. Freedland

Summary: This study compares public interest in FDA-approved drugs for advanced prostate cancer and finds that Bicalutamide remains relatively popular, especially among lower-income individuals, those without health insurance, and in states that did not expand Medicaid.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Meeting Abstract Oncology

Serum Filamin A is a prognostic biomarker for screening benign prostatic hyperplasia vs prostate cancer in Caucasian and African American men

Nischal Mahaveer Chand, Poornima K. Tekumalla, Albert Dobi, Amina Ali, Gregory M. Miller, Juan J. Aristizabal-Henao, Elder Granger, Stephen J. Freedland, Shiv Srivastava, Jose Arturo Rodriguez Rivera, Arturo Mendoza, David G. McLeod, Niven R. Narain, Michael A. Kiebish

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Contemporary use of wearable activity monitors in prostate cancer survivors: A scoping review.

Brandon Noorvash, Carolina Raines, Edwin Melencio Posadas, Howard M. Sandler, Stephen J. Freedland, Gillian Gresham

JOURNAL OF CLINICAL ONCOLOGY (2023)

Review Urology & Nephrology

Genetic and biological drivers of prostate cancer disparities in Black men

Jun Gong, Daniel M. Kim, Michael R. Freeman, Hyung Kim, Leigh Ellis, Bethany Smith, Dan Theodorescu, Edwin Posadas, Robert Figlin, Neil Bhowmick, Stephen J. Freedland

Summary: Black men with prostate cancer have biologically distinct cancers compared to white men, including genetic alterations, protein differences, and tumor microenvironment. Socioeconomic status partially explains the disparities, but not completely. Further research on these biological differences can guide efforts to improve treatment outcomes for Black men.

NATURE REVIEWS UROLOGY (2023)

Article Urology & Nephrology

A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients

Stephen J. Freedland, Sandhya Nair, Xiwu Lin, Lawrence Karsh, Christopher Pieczonka, Ravi Potluri, Sabine D. Brookman-May, Suneel D. Mundle, Sarah Fleming, Neeraj Agarwal

Summary: This study evaluated patient characteristics, treatment patterns, and outcomes in men with localized or locally advanced prostate cancer using real-world data.

WORLD JOURNAL OF UROLOGY (2023)

No Data Available